LEUNASE

This brand name is authorized in Hong Kong SAR China, Japan, Mexico, Singapore, Turkey.

Active ingredients

The drug LEUNASE contains one active pharmaceutical ingredient (API):

1	L-asparaginase UNII G4FQ3CKY5R - ASPARAGINASE
	Asparaginase hydrolyses asparagine to aspartic acid and ammonia. In contrast to normal cells, lymphoblastic tumour cells have a very limited capacity for synthesising asparagine because of a significantly reduced expression of asparagine synthetase. Therefore, they require asparagine which diffuses from the extracellular environment. As a result of asparaginase-induced asparagine depletion in serum, protein synthesis in lymphoblastic tumour cells is disturbed while sparing most normal cells.
	Read more about Asparaginase

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XX02	Asparaginase	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
HK	Department of Health Drug Office	01122
JP	医薬品医療機器総合機構	4291400A1033, 4291400A2030
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	158M88
SG	Health Sciences Authority	01989P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699650791318